204 related articles for article (PubMed ID: 25481455)
1. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Sommariva S; Tarricone R; Lazzeri M; Ricciardi W; Montorsi F
Eur Urol; 2016 Jan; 69(1):107-15. PubMed ID: 25481455
[TBL] [Abstract][Full Text] [Related]
2. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
4. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.
Crawford ED; Scholz MC; Kar AJ; Fegan JE; Haregewoin A; Kaldate RR; Brawer MK
Curr Med Res Opin; 2014 Jun; 30(6):1025-31. PubMed ID: 24576172
[TBL] [Abstract][Full Text] [Related]
8. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
10. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review.
Harnden P; Shelley MD; Naylor B; Coles B; Mason MD
Eur Urol; 2008 Oct; 54(4):728-39. PubMed ID: 18603352
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
12. Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients.
Oderda M; Cozzi G; Daniele L; Sapino A; Munegato S; Renne G; De Cobelli O; Gontero P
Urology; 2017 Apr; 102():73-78. PubMed ID: 27894974
[TBL] [Abstract][Full Text] [Related]
13. Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(6):1-75. PubMed ID: 28572867
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a cell cycle progression score for men with prostate cancer.
Cuzick J
Recent Results Cancer Res; 2014; 202():133-40. PubMed ID: 24531787
[TBL] [Abstract][Full Text] [Related]
15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
16. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
Chade DC; Eastham J; Graefen M; Hu JC; Karnes RJ; Klotz L; Montorsi F; van Poppel H; Scardino PT; Shariat SF
Eur Urol; 2012 May; 61(5):961-71. PubMed ID: 22280856
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
18. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
van den Bergh RC; van Casteren NJ; van den Broeck T; Fordyce ER; Gietzmann WK; Stewart F; MacLennan S; Dabestani S; Bellmunt J; Bolla M; Briers E; Cornford P; Joniau S; Mason MD; Matveev V; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Lam TB; Mottet N
Eur Urol; 2016 May; 69(5):802-20. PubMed ID: 26691493
[TBL] [Abstract][Full Text] [Related]
19. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]